Exact Mass: 662.3831859999999
Exact Mass Matches: 662.3831859999999
Found 311 metabolites which its exact mass value is equals to given mass value 662.3831859999999,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
CLINDAMYCIN PALMITATE
C34H63ClN2O6S (662.4095128000001)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D055231 - Lincosamides D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors
Prosapogenin
Saponin from peel of Quillaja saponaria (soap-bark tree). Saponin from peel of Quillaja saponaria (soap-bark tree)
1-Acetyl-3,27-dihydroxywitha-5,24-dienolide 3-glucoside
1-Acetyl-3,27-dihydroxywitha-5,24-dienolide 3-glucoside is found in fruits. 1-Acetyl-3,27-dihydroxywitha-5,24-dienolide 3-glucoside is a constituent of Physalis peruviana (Cape gooseberry). Constituent of Physalis peruviana (Cape gooseberry). 1-Acetyl-3,27-dihydroxywitha-5,24-dienolide 3-glucoside is found in fruits.
Physalolactone B 3-glucoside
Physalolactone B 3-glucoside is found in fruits. Physalolactone B 3-glucoside is a constituent of Physalis peruviana (Cape gooseberry). Constituent of Physalis peruviana (Cape gooseberry). Physalolactone B 3-glucoside is found in fruits.
[(2R,5S)-5-(Octadecylcarbamoyloxymethyl)oxolan-2-yl]methyl 2-quinolin-1-ium-1-ylethyl phosphate
PA(10:0/PGF2alpha)
C33H59O11P (662.3794793999999)
PA(10:0/PGF2alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/PGF2alpha), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of Prostaglandin F2alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(PGF2alpha/10:0)
C33H59O11P (662.3794793999999)
PA(PGF2alpha/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGF2alpha/10:0), in particular, consists of one chain of one Prostaglandin F2alpha at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(10:0/PGE1)
C33H59O11P (662.3794793999999)
PA(10:0/PGE1) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/PGE1), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of Prostaglandin E1 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(PGE1/10:0)
C33H59O11P (662.3794793999999)
PA(PGE1/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGE1/10:0), in particular, consists of one chain of one Prostaglandin E1 at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(10:0/PGD1)
C33H59O11P (662.3794793999999)
PA(10:0/PGD1) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/PGD1), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of Prostaglandin D1 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(PGD1/10:0)
C33H59O11P (662.3794793999999)
PA(PGD1/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGD1/10:0), in particular, consists of one chain of one Prostaglandin D1 at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(12:0/5-iso PGF2VI)
C33H59O11P (662.3794793999999)
PA(12:0/5-iso PGF2VI) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/5-iso PGF2VI), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 5-iso Prostaglandin F2alpha-VI at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(5-iso PGF2VI/12:0)
C33H59O11P (662.3794793999999)
PA(5-iso PGF2VI/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(5-iso PGF2VI/12:0), in particular, consists of one chain of one 5-iso Prostaglandin F2alpha-VI at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(i-12:0/5-iso PGF2VI)
C33H59O11P (662.3794793999999)
PA(i-12:0/5-iso PGF2VI) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/5-iso PGF2VI), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 5-iso Prostaglandin F2alpha-VI at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(5-iso PGF2VI/i-12:0)
C33H59O11P (662.3794793999999)
PA(5-iso PGF2VI/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(5-iso PGF2VI/i-12:0), in particular, consists of one chain of one 5-iso Prostaglandin F2alpha-VI at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
Acetylcimigenol arabinoside
23-O-Acetylshengmanol-3-o-alpha-L-arabinoside is a natural product found in Actaea cimicifuga and Actaea racemosa with data available. See also: Black Cohosh (part of). Acetylshengmanol Arabinoside is isolated from Cimicifugae rhizoma. Acetylshengmanol Arabinoside is isolated from Cimicifugae rhizoma.
Hederagenin 3-O-beta-D-glucuronopyranoside 6-O-methyl ester
Prostaglandin E2-biotin
protoconstipatic acid (18S)-18-O-alpha-D-arabinofuranosyl-(1-6)-beta-D-glucopyranoside
3-O-beta-D-Glucopyranuronoside-3-Hydroxy-12-oleanene-23,28-dioic acid
alo-murolic acid (18R)-18-O-1-beta-xylopyranosyl-(1-6)-beta-D-glucopyranoside
2-{[2,4,6-trihydroxy-5-(3,7-dimethyl-2,6-octadienyl)-3-butanoylphenyl]methyl}-3,5-dihydroxy-4-methyl-4-(3,7-dimethyl-2,6-octadienyl)-6-acetyl-2,5-cyclohexadien-1-one|yungensin E
16-decarbomethoxyvoacamine-pseudoindoxyl
C41H50N4O4 (662.3831859999999)
murolic acid (18R)-18-O-beta-D-apiofuranosyl-(1-2)-beta-D-glucopyranoside
3-O-beta-D-glucopyranosylserjanic acid|serjanic acid 3-O-(beta-D-glucopyranoside)
(3beta,5alpha,6beta,15alpha,22E,24R)-Cholest-4-ene-3,6,8,15,24-pentol
C32H54O12S (662.3335804000001)
protoconstipatic acid (18S)-18-O-beta-D-apiofuranosyl-(1-4)-beta-D-glucopyranoside
24-epi-24-O-acetylhydroshengmanol 3-beta-D-xylopyranoside (delta-16,17)-enol ether|24-epi-O-acetylhydroshengmanol 3-beta-D-xylopyranoside (delta-16,17)-enolether
3-O-beta-D-glucuronopyranosyl echinocystic acid|Eclalbasaponin XIII|Tragopogonsaponin A Methyl Ester
methyl 3beta-O-(4-O-methyl-E-cinnamoyl)-arjunolate
3-O-beta-D-methyl glucopyranosiduronate-2beta-hydroxyoleanolic acid|caryocaroside IV-6
(3beta,9beta,15alpha,16beta,23R,24R)-15,16-dihydroxy-3-(beta-D-xylopyranosyloxy)-16,23-epoxy-9,19-cyclolanost-25-en-24-yl acetate|24-O-acetyl-25-anhydroshengmanol-3-O-beta-D-xylopyranoside
cimigenol-3-O-[4-O-acetyl-alpha-L-arabinopyranoside]
shengmanol-3-O-[2-O-acetyl-alpha-L-arabinopyranoside]
(1R)-1alpha,11alpha,22alpha-trihydroxy-3,4-seco-lupa-4(23),20(30)-diene-3,28-dioic acid3,11-lactone 28-O-beta-D-glucopyranoside|acanthosessilioside F
gardeniside B|siaresinolic acid 3-O-beta-D-glucuronopyranoside-6?-O-methyl ester
methyl 3alpha-trans-feruloyloxy-2alpha-hydroxyurs-12-en-28-oate
gnidilatimonoein
A diterpenoid isolated from the leaves of Daphne mucronata and exhibits anti-tumour and anti-metastatic activities.
3beta,24-dihydroxy-22-oxo-12-oleanen-29-oic acid 3-O-beta-D-glucuropyranoside|caraganin B
3-O-beta-D-glucuronopyranosyl-3beta,24-dihydroxy-11alpha-methoxyolean-12-en-22-one|sarosiensin VII
3beta-hydroxy-21beta-E-dimethylcaffeoyloxyolean-12-en-28-oic acid
(20S*,22R*,23S*,24R*)-16beta:23:22:25-diepoxy-3beta,23,24-trihydroxy-9,19-cyclolanostane-3-O-beta-D-(3-acetyl)xylopyranoside|soulieoside E
19alpha-hydroxyurs-12-ene-24,28-dioate 3-O-beta-xylopyranoside
(3beta,6alpha,15beta,24S)-Cholest-4-ene-3,6,8,15,24-pentol
C32H54O12S (662.3335804000001)
allo-murolic acid (18R)-18-O-beta-D-apiofuranosyl-(1-6)-beta-D-glucopyranoside
28-beta-D-glucopyranosyl 30-methyl 3beta-hydroxyolean-12-ene-28,30-dioate
(22S)-cholesta-5,24-diene-3beta,11alpha,16beta,22-tetrol 16-O-(2,3-di-O-acetyl-alpha-L-rhamnopyranoside)|(22S)-Cholesta-5,24-diene-3??,11??,16??,22-tetrol 16-O-(2,3-di-O-acetyl-??-L-rhamnopyranoside)
3beta,3,30-dihydroxyursa-12,19-diene-24,28-dioic acid 28-O-beta-D-glucopyranoside|ilexhainanoside B
butyl 3-O-butanoyl-4,6,4-tri(O-2-methylpropanoyl)neohesperidoside
25-AC-xylopyranoside
Cimigenoside, 25-acetate is a natural product found in Actaea pachypoda, Actaea dahurica, and other organisms with data available. See also: Black Cohosh (part of).
PicfeltarraeninX
Acetylshengmanol xyloside
23-O-acetylshengmanol 3-O-beta-D-xylopyranoside is a triterpenoid. It has a role as a metabolite. 23-O-acetylshengmanol-3-O-beta-D-xylopyranoside is a natural product found in Actaea pachypoda and Actaea racemosa with data available. See also: Black Cohosh (part of).
C37H58O10_(3beta,5xi,9beta,15alpha,23R,24S)-3-(alpha-L-Arabinopyranosyloxy)-15-hydroxy-16-oxo-24,25-epoxy-9,19-cyclolanostan-23-yl acetate
1-Acetyl-3,27-dihydroxywitha-5,24-dienolide 3-glucoside
Physalolactone B 3-glucoside
prosapogenin
15-(2-O-beta-D-glucopyranosyl-beta-D-glucopyranosyloxy)hexadecanoic acid 1,4-lactone 6,6-diacetate
16-(2-O-beta-D-glucopyranosyl-beta-D-glucopyranosyloxy)hexadecanoic acid 1,4-lactone 6,6-diacetate
OHDdiA-PA
C33H59O11P (662.3794793999999)
cimicifoetiside A
Cimifoetidanoside G
Evasterioside B
C32H54O12S (662.3335804000001)
Butyl 3-O-butanoyl-4,6,4-tri-O-(2-methylpropanoyl)-neohesperidoside
Zirconium(2+) bis(2-ethylhexanoate)
C32H60O8Zr (662.3335040000001)
Fruticoside F
A steroid saponin that is ergosta-7,24(28)-diene-21-thioic S-acid attached to an acetyloxy group at position 2, an alpha-L-quinovopyranosyloxy group at position 3 and a methyl group at position 4 (the 2alpha,3beta,4alpha,5alpha stereoisomer). It has been isolated from the roots of Breynia fruticosa.
[(2R,5S)-5-(Octadecylcarbamoyloxymethyl)oxolan-2-yl]methyl 2-quinolin-1-ium-1-ylethyl phosphate
N-[[(3S,9S,10S)-16-[[(4-fluoroanilino)-oxomethyl]amino]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methyl-2-phenylacetamide
C37H47FN4O6 (662.3479454000001)
L-leucyl-L-seryl-L-alpha-glutamyl-L-threonyl-L-threonyl-D-leucine
[(3S,5S,6R,8S,9R,10S,13R,14S,15S,17R)-6,8,15-trihydroxy-10,13-dimethyl-17-[(E,2R)-6-methyl-5-[(2S,3S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyhept-3-en-2-yl]-1,2,3,4,5,6,7,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate
C32H54O12S (662.3335804000001)
2-[hydroxy-[(2R)-2-[(E)-4-hydroxy-7-oxohept-5-enoyl]oxy-3-[(Z)-octadec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium
N-[5-[4-[3,6-bis(dimethylamino)acridin-10-ium-10-yl]butanoylamino]pentyl]-5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanamide
[1-hexanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate
[1-[(2-heptanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate
[1-[(2-hexanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (13Z,16Z)-docosa-13,16-dienoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-nonanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-octanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (11Z,14Z)-icosa-11,14-dienoate
[1-[(2-acetyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (15Z,18Z)-hexacosa-15,18-dienoate
[1-[(2-butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (13Z,16Z)-tetracosa-13,16-dienoate
[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (Z)-tetradec-9-enoate
[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (Z)-pentadec-9-enoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-undecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate
[1-[(2-decanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate
[1-[(2-dodecanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate
[1-butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (13Z,16Z)-tetracosa-13,16-dienoate
[1-acetyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (15Z,18Z)-hexacosa-15,18-dienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (11Z,14Z)-icosa-11,14-dienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (13Z,16Z)-docosa-13,16-dienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-nonanoyloxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate
[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropyl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(Z)-tetradec-9-enoyl]oxypropyl] (Z)-tetradec-9-enoate
[1-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecanoyloxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate
[1-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-phosphonooxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (Z)-pentadec-9-enoate
[1-decanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate
[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (11E,13E,15E)-octadeca-11,13,15-trienoate
[(2S)-2-decanoyloxy-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropyl] (9E,11E)-octadeca-9,11-dienoate
[1-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate
[(2S)-2-decanoyloxy-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropyl] (6E,9E)-octadeca-6,9-dienoate
[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate
[(2R)-1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (6E,9E)-octadeca-6,9-dienoate
[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-phosphonooxypropyl] (7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoate
[(2S)-2-decanoyloxy-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropyl] (2E,4E)-octadeca-2,4-dienoate
[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (E)-tetradec-9-enoate
[1-[(6E,9E)-dodeca-6,9-dienoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate
[(2S)-2-decanoyloxy-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropyl] (9E,12E)-octadeca-9,12-dienoate
[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (9E,12E)-heptadeca-9,12-dienoate
[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-undecanoyloxypropyl] (9E,12E)-heptadeca-9,12-dienoate
[(2R)-1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (9E,12E)-octadeca-9,12-dienoate
[1-[(E)-dodec-5-enoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate
[(2R)-1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (2E,4E)-octadeca-2,4-dienoate
[(2R)-1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (9E,11E)-octadeca-9,11-dienoate
[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (10E,12E)-octadeca-10,12-dienoate
[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate
2-[[3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
23-O-acetylshengmanol 3-O-beta-D-xylopyranoside
A natural product found in Actaea racemosa.
1,2-di-(9Z-tetradecenoyl)-sn-glycero-3-phospho-(1-sn-glycerol)
25-O-acetylcimigenol 3-O-alpha-L-arabinopyranoside
A natural product found in Actaea racemosa.
MGDG(28:6)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
(4as,5r,6s,8ar,9ar)-9a-[(4as,5r,6s,8ar,9ar)-3,4a,5-trimethyl-6-{[(2z)-2-methylbut-2-enoyl]oxy}-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-9a-yl]-3,4a,5-trimethyl-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-6-yl (2z)-2-methylbut-2-enoate
(4as,5r,6s,8ar,9as)-9a-[(4as,5r,6s,8ar,9as)-3,4a,5-trimethyl-6-{[(2z)-2-methylbut-2-enoyl]oxy}-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-9a-yl]-3,4a,5-trimethyl-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-6-yl (2z)-2-methylbut-2-enoate
2-[(2-{[4,5-dihydroxy-6-(hydroxymethyl)-2-[(2,6,10-trimethyldodeca-2,6,10-trien-1-yl)oxy]oxan-3-yl]oxy}-4,5-dihydroxy-6-methyloxan-3-yl)oxy]oxane-3,4,5-triol
2-{14-[(3-{[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl)oxy]pentadecyl}-4-methylidene-5-oxooxolane-3-carboxylic acid
(1r,3r)-1-[(2s)-3,3-dimethyloxiran-2-yl]-3-[(1s,3r,6s,8r,11r,12s,13r,15r,16r)-13-hydroxy-7,7,12,16-tetramethyl-14-oxo-6-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]butyl acetate
(3s,6s,9r,12s,16r)-3,9-dibenzyl-5,8,11,14-tetrahydroxy-6,12-bis(2-methylpropyl)-16-pentyl-1-oxa-4,7,10,13-tetraazacyclohexadeca-4,7,10,13-tetraen-2-one
methyl (1s,12r,14s,18s)-12-[(1's,2s,3'r,8's,9's)-9'-ethyl-5-methoxy-3-oxo-1h-7'-azaspiro[indole-2,4'-tricyclo[5.3.1.0³,⁸]undecan]-6-yl]-15-ethylidene-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate
C41H50N4O4 (662.3831859999999)
(2r,3r,4r,5s,6s)-2-{[(1s,2s,3as,3bs,7s,9ar,9bs,10r,11as)-7,10-dihydroxy-1-[(2s,3s)-3-hydroxy-6-methylhept-5-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-2-yl]oxy}-4-(acetyloxy)-5-hydroxy-6-methyloxan-3-yl acetate
(1r)-1-[(1s,4r,5r,6r,8r,10r,11r,12s,13r,16r,18s,21r)-10,11-dihydroxy-4,6,12,17,17-pentamethyl-18-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-8-yl]-2-methylprop-2-en-1-yl acetate
(1s)-2-hydroxy-2-methyl-1-[(1s,4r,5r,6r,8r,10r,12s,13r,16r,18s,21r)-4,6,12,17,17-pentamethyl-11-oxo-18-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-8-yl]propyl acetate
(3r,4r,5r,6s)-6-{[(1s,2s,5r,7s,10r,12s,15r,16r,17s,18r,21r,22s,24s)-21,22-dihydroxy-1,6,6,15,17,20,20-heptamethyl-19,23-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹⁰.0¹⁰,¹².0¹⁶,²⁴.0¹⁸,²²]pentacosan-7-yl]oxy}-4,5-dihydroxyoxan-3-yl acetate
2-[(1s,2r,3s,4r,7r,9s,12r,14s,17r,18r,19r,21r,22r)-2-hydroxy-3,8,8,17,19-pentamethyl-9-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracosan-22-yl]propan-2-yl acetate
25-acetylcimigenol xyloside
{"Ingredient_id": "HBIN004597","Ingredient_name": "25-acetylcimigenol xyloside","Alias": "NA","Ingredient_formula": "C37H58O10","Ingredient_Smile": "NA","Ingredient_weight": "662.859","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "8738","PubChem_id": "NA","DrugBank_id": "NA"}
25-o-acetylcimigenoside
{"Ingredient_id": "HBIN004705","Ingredient_name": "25-o-acetylcimigenoside","Alias": "NA","Ingredient_formula": "C37H58O10","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "354","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
acetyl shengmanol xyloside
{"Ingredient_id": "HBIN014492","Ingredient_name": "acetyl shengmanol xyloside","Alias": "NA","Ingredient_formula": "C37H58O10","Ingredient_Smile": "CC(CC(C1C(O1)(C)C)OC(=O)C)C2C(=O)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7C(C(C(CO7)O)O)O)C)C)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "513","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
beesioside l
{"Ingredient_id": "HBIN017688","Ingredient_name": "beesioside l","Alias": "NA","Ingredient_formula": "C37H58O10","Ingredient_Smile": "CC(=O)OC1CC2(C3CCC4C(C(CCC45C3(C5)CCC26C1C7(CCC(O7)(OC6)C(C)(C)O)C)OC8C(C(C(CO8)O)O)O)(C)C)C","Ingredient_weight": "662.8 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "2205","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "10995951","DrugBank_id": "NA"}
beesioside o
{"Ingredient_id": "HBIN017691","Ingredient_name": "beesioside o","Alias": "NA","Ingredient_formula": "C37H58O10","Ingredient_Smile": "CC(=O)OC1C2C(C3(C1(C4CCC5C(C(CCC56C4(C6)CC3)OC7C(C(C(CO7)O)O)O)(C)C)C)C)C8(CCC(O2)(O8)C(C)(C)O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "2208","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
4,8a-dimethyl (3s,4s,4ar,6ar,6bs,8as,11r,12r,12as,14ar,14br)-12-hydroxy-4,6a,6b,11,12,14b-hexamethyl-3-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylate
(2r,3s,4s,5r)-6-({2-[(1ar,2r,4ar,7r,8ar)-2,7-dihydroxy-4a-methyl-8-methylidene-hexahydronaphtho[1,8a-b]oxiren-2-yl]propan-2-yl}oxy)-2-methyl-5-{[(2z)-2-methylbut-2-enoyl]oxy}-4-[(2-methylbutanoyl)oxy]oxan-3-yl (2z)-2-methylbut-2-enoate
(2r,3r,4s,5s,6r)-2-{[(1r,4s,5r,9r,10s,13r,14r,15r)-14-hydroxy-14-(hydroxymethyl)-5,9-dimethyl-15-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-5-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol
2-[(1s,2r,3s,4r,7r,9s,12r,14s,17r,18r,19r,21r,22s)-2-hydroxy-3,8,8,17,19-pentamethyl-9-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracosan-22-yl]propan-2-yl acetate
2-[(1s,2r,3s,4r,7r,9s,12r,14s,17r,18r,19r,21r,22r)-2-hydroxy-3,8,8,17,19-pentamethyl-9-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracosan-22-yl]propan-2-yl acetate
(2s,3r)-2-[(14s)-14-{[(2r,3r,4s,5s,6r)-3-{[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentadecyl]-4-methylidene-5-oxooxolane-3-carboxylic acid
2-methyl 4a-(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2s,4ar,6as,6br,8ar,10s,12ar,12br,14bs)-10-hydroxy-2,6a,6b,9,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-2,4a-dicarboxylate
(4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-10-{[(2r,3r,4s,5s,6s)-3,4,5-trihydroxy-6-(methoxycarbonyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid
2-acetyl-6-{[3-butanoyl-5-(3,7-dimethylocta-2,6-dien-1-yl)-2,4,6-trihydroxyphenyl]methyl}-4-(3,7-dimethylocta-2,6-dien-1-yl)-3,5-dihydroxy-4-methylcyclohexa-2,5-dien-1-one
2-hydroxy-2-methyl-1-{4,6,12,17,17-pentamethyl-11-oxo-18-[(3,4,5-trihydroxyoxan-2-yl)oxy]-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-8-yl}propyl acetate
(1r,3r,4r,5r,6r,8s,10s,12s,13s,16r,18s,21r)-8-hydroxy-4,6,12,17,17-pentamethyl-8-(2-methylpropanoyl)-18-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-3-yl acetate
(4ar,6br,10s,12ar,14bs)-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-10-{[(2r,3r,4s,5s,6s)-3,4,5-trihydroxy-6-(methoxycarbonyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid
2-{[14-hydroxy-14-(hydroxymethyl)-5,9-dimethyl-15-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-5-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol
methyl (4as,6as,6br,8ar,9r,10r,11r,12ar,12br,14bs)-10,11-dihydroxy-9-({[(2e)-3-(4-methoxyphenyl)prop-2-enoyl]oxy}methyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate
(2r,3s,4s,5s)-2-{[(2s,3s,4s,5r,6s)-2-{[(2s,3r,4s,5s,6s)-4,5-dihydroxy-6-(hydroxymethyl)-2-{[(2e,6e,10e)-2,6,10-trimethyldodeca-2,6,10-trien-1-yl]oxy}oxan-3-yl]oxy}-4,5-dihydroxy-6-methyloxan-3-yl]oxy}oxane-3,4,5-triol
methyl (1s,12r,14s,15e,18s)-12-[(1's,2s,3'r,8's,9's)-9'-ethyl-5-methoxy-3-oxo-1h-7'-azaspiro[indole-2,4'-tricyclo[5.3.1.0³,⁸]undecan]-6-yl]-15-ethylidene-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate
C41H50N4O4 (662.3831859999999)
n-[5,14-bis(acetyloxy)-7-[(acetyloxy)methyl]-15-[1-(dimethylamino)ethyl]-7,12,16-trimethyltetracyclo[9.7.0.0³,⁸.0¹²,¹⁶]octadeca-1(18),3-dien-6-yl]benzenecarboximidic acid
(1r,2s,7s)-7-{4-[(1r,2s)-7-chloro-1-hydroxy-2-methylundecyl]-2,6-dihydroxyphenyl}-1-(3,5-dihydroxyphenyl)-2-methylundecyl acetate
9a-{3,4a,5-trimethyl-6-[(2-methylbut-2-enoyl)oxy]-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-9a-yl}-3,4a,5-trimethyl-2-oxo-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-6-yl 2-methylbut-2-enoate
(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1r,2r,5s,6s,8r,9r,10r,12r,16r,17s,18s,21s)-6,16-dihydroxy-1,2,17-trimethyl-14-oxo-8,18-bis(prop-1-en-2-yl)-13-oxapentacyclo[10.8.1.0²,¹⁰.0⁵,⁹.0¹⁷,²¹]henicosane-5-carboxylate
1-{10,11-dihydroxy-4,6,12,17,17-pentamethyl-18-[(3,4,5-trihydroxyoxan-2-yl)oxy]-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-8-yl}-2-methylprop-2-en-1-yl acetate
(2r,3r,4s,5s,6r)-3-(acetyloxy)-2-[(acetyloxy)methyl]-5-(propanoyloxy)-6-[(2r,3s)-2,3,4-trihydroxybutoxy]oxan-4-yl hexadecanoate
(2e,6e,8z)-10-{9-butyl-8-[(3e)-4-carboxy-3-methylbut-3-en-1-yl]-9-[(3-carboxypropanoyl)oxy]-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl}-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid
(1r)-2-hydroxy-2-methyl-1-[(1s,4r,5r,6r,8r,10r,12s,13r,16r,18s,21r)-4,6,12,17,17-pentamethyl-11-oxo-18-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan-8-yl]propyl acetate
(1r,3r)-1-[(2s)-3,3-dimethyloxiran-2-yl]-3-[(1s,3r,6s,8r,11r,12s,13r,15r,16r)-13-hydroxy-7,7,12,16-tetramethyl-14-oxo-6-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]butyl acetate
(2s,3s,4s,5r,6r)-6-{[(3s,4s,4ar,6ar,6bs,8ar,12s,12as,14ar,14br)-8a-carboxy-4-formyl-12-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid
(4ar,5r,6as,6br,8ar,10s,12ar,12br,14bs)-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-10-{[(2r,3r,4s,5s,6s)-3,4,5-trihydroxy-6-(methoxycarbonyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid
2-({21,22-dihydroxy-1,6,6,15,17,20,20-heptamethyl-19,23-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹⁰.0¹⁰,¹².0¹⁶,²⁴.0¹⁸,²²]pentacosan-7-yl}oxy)-3,5-dihydroxyoxan-4-yl acetate
6-[(8a-carboxy-4-formyl-12-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl)oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
(2s,3r,4s,5r)-2-{[(1s,2s,5r,7s,10r,12s,15r,16r,17s,18r,21r,22r,24s)-21,22-dihydroxy-1,6,6,15,17,20,20-heptamethyl-19,23-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹⁰.0¹⁰,¹².0¹⁶,²⁴.0¹⁸,²²]pentacosan-7-yl]oxy}-3,5-dihydroxyoxan-4-yl acetate
(1r,3as,3bs,7r,9s,9ar,9bs,11as)-1-[(1s)-1-[(2r)-5-(hydroxymethyl)-4-methyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]-9a,11a-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-9-yl acetate
(4as,6as,6br,8ar,10r,11s,12ar,12br,14bs)-11-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-10-{[(2r,3r,4s,5s,6s)-3,4,5-trihydroxy-6-(methoxycarbonyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid
methyl 10,11-dihydroxy-9-({[3-(4-methoxyphenyl)prop-2-enoyl]oxy}methyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate
2-methyl 4a-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] 10-hydroxy-2,6a,6b,9,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-2,4a-dicarboxylate
(2s,4ar,6as,6br,8ar,10s,12ar,12br,14br)-2-(methoxycarbonyl)-2,6a,6b,9,9,12a-hexamethyl-10-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid
2-({2-butoxy-4-hydroxy-5-[(2-methylpropanoyl)oxy]-6-{[(2-methylpropanoyl)oxy]methyl}oxan-3-yl}oxy)-3-hydroxy-6-methyl-5-[(2-methylpropanoyl)oxy]oxan-4-yl butanoate
(4r)-2-acetyl-6-({3-butanoyl-5-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-2,4,6-trihydroxyphenyl}methyl)-4-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-3,5-dihydroxy-4-methylcyclohexa-2,5-dien-1-one
2-(methoxycarbonyl)-2,6a,6b,9,9,12a-hexamethyl-10-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid
(1s,3r)-1-[(2s)-3,3-dimethyloxiran-2-yl]-3-[(1s,3r,6s,8r,11r,12s,13r,15r,16r)-13-hydroxy-7,7,12,16-tetramethyl-14-oxo-6-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]butyl acetate
1-(3,3-dimethyloxiran-2-yl)-3-{13-hydroxy-7,7,12,16-tetramethyl-14-oxo-6-[(3,4,5-trihydroxyoxan-2-yl)oxy]pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl}butyl acetate
(2s,3r)-2-[(14s)-14-{[(2r,3r,4r,5s,6r)-5-{[(3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentadecyl]-4-methylidene-5-oxooxolane-3-carboxylic acid
9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-10-{[3,4,5-trihydroxy-6-(methoxycarbonyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid
3-(acetyloxy)-2-[(acetyloxy)methyl]-5-(propanoyloxy)-6-(2,3,4-trihydroxybutoxy)oxan-4-yl hexadecanoate
(2r,3r,4r,5s,6s)-2-{[(1r,2s,3as,3bs,7s,9ar,9bs,10r,11as)-7,10-dihydroxy-1-[(2s,3s)-3-hydroxy-6-methylhept-5-en-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-2-yl]oxy}-4-(acetyloxy)-5-hydroxy-6-methyloxan-3-yl acetate
(1r,3r)-1-[(2r)-3,3-dimethyloxiran-2-yl]-3-[(1s,3r,6s,8r,11r,12s,13r,15r,16r)-13-hydroxy-7,7,12,16-tetramethyl-14-oxo-6-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]butyl acetate
[(1r,3r,3as,3bs,5s,5as,7s,9as,9br,11ar)-3,3b,5-trihydroxy-9a,11a-dimethyl-1-[(2r,3e,5r)-6-methyl-5-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}hept-3-en-2-yl]-tetradecahydrocyclopenta[a]phenanthren-7-yl]oxidanesulfonic acid
C32H54O12S (662.3335804000001)
7-[4-(7-chloro-1-hydroxy-2-methylundecyl)-2,6-dihydroxyphenyl]-1-(3,5-dihydroxyphenyl)-2-methylundecyl acetate
(1r,3r,4r,5r,6s,10s,12s,13s,16r,18s,21r)-8-(1,2-dihydroxy-2-methylpropyl)-4,6,12,17,17-pentamethyl-18-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-9-oxahexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docos-7-en-3-yl acetate
[(1r,3r,3as,3bs,5s,5as,7s,9as,9br,11ar)-3,3b,5-trihydroxy-9a,11a-dimethyl-1-[(2s,3e,5r)-6-methyl-5-{[(2r,3s,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}hept-3-en-2-yl]-tetradecahydrocyclopenta[a]phenanthren-7-yl]oxidanesulfonic acid
C32H54O12S (662.3335804000001)